Clinical trials show promise in leukemia

July 10, 2018 by Anna Williams, Northwestern University
Bone marrow aspirate showing acute myeloid leukemia. Several blasts have Auer rods. Credit: Wikipedia

Two drugs that target different mutations showed encouraging results in treating leukemia, according to recent clinical trials published in the New England Journal of Medicine (NEJM) and The Lancet Oncology.

Jessica Altman, MD, '07 GME, associate professor of Medicine in the Division of Hematology and Oncology and director of the Acute Leukemia Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, was a co-author of both studies.

Acute myeloid leukemia (AML), the most common type of adult leukemia, is a cancer of the blood-forming cells of the bone marrow. Currently, most with AML are treated with standard chemotherapy. But recent scientific advances have revealed that there are many forms of the disease, each with different specific genetic changes that may affect cancer growth and treatment.

As such, there has been increasing research into the development of new targeted therapies that inhibit specific found in AML. These therapies are especially important for patients who are unable to tolerate chemotherapy, or whose cancer has relapsed after standard treatment.

Targeting the IDH1 Enzyme

Mutations in the gene for an enzyme called isocitrate dehydrogenases 1 (IDH1) are found in roughly 5 to 10 percent of adults with AML, and these changes are thought to be a driver of the disease.

In a recent phase I clinical trial, a team of investigators evaluated the safety and efficacy of an oral medication that specifically inhibits mutated IDH1, called ivosidenib. The findings were published in the NEJM.

The trial included 258 patients with AML who were positive for the IDH1 mutation; 179 of them had relapsed or refractory AML.

The investigators found that ivosidenib, delivered at a dose of 500 mg daily, showed favorable results among patients with advanced relapsed or refractory AML and was well tolerated with a low rate of serious adverse events. The complete remission rate (including patients who did not have a full blood count recovery) was around 30 percent.

"We saw an encouraging rate of response compared to standard chemotherapy in this patient population, with relatively few toxicities," Altman said.

Further investigations of ivosidenib are now ongoing. According to Altman, other inhibitors of IDH1 are also currently in development, and a drug called enasidenib that inhibits a related enzyme, IDH2, was approved by the Food and Drug Administration last year for adults with IDH2-mutated relapsed or refractory AML.

The NEJM study, a multi-center trial, was supported by Agios Pharmaceuticals, which owns ivosidenib.

Targeting the FLT3 Protein

About 30 percent of patients with AML have mutations in a different driver gene, called FLT3. The mutation is associated with particularly poor outcomes, especially among older patients and in those with a certain type of the mutation called FLT3-ITD.

In a phase II trial published in The Lancet Oncology, investigators assessed the efficacy and safety of quizartinib, a drug that inhibits FLT3, among patients with refractory or relapsed AML.

The study, which enrolled 333 patients, included two cohorts: one of patients 60 years or older with relapsed or refractory AML within one year of first-line therapy, and a second of patients 18 years or older with relapsed or refractory AML following chemotherapy or stem cell transplantation.

The trial found that quizartinib was generally well-tolerated and had a high rate of response, particularly among patients who were FLT3-ITD positive. The composite complete remission rate was around 50 percent.

According to the authors, the findings confirm that targeting the FLT3 mutation with a selective inhibitor is a promising strategy for improving outcomes in this patient population.

Randomized clinical trials evaluating quizartinib in other settings are ongoing, and other FLT3 inhibitors are also currently in development, Altman notes. There is also an already approved drug, called midostaurin, that has been shown to improve survival for patients with FLT3-mutated AML when combined with chemotherapy, compared to chemotherapy alone.

"Thus, it is possible we may be in a situation where there are choices of FLT3 inhibitors for patients with FLT3-mutated AML," Altman said.

Explore further: Study of acute myeloid leukemia patients shows protein inhibitor drug safe and effective with durable remissions

More information: Courtney D. DiNardo et al. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML, New England Journal of Medicine (2018). DOI: 10.1056/NEJMoa1716984

Jorge Cortes et al. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial, The Lancet Oncology (2018). DOI: 10.1016/S1470-2045(18)30240-7

Related Stories

Study of acute myeloid leukemia patients shows protein inhibitor drug safe and effective with durable remissions

June 3, 2018
Ivosidenib, an experimental drug that inhibits a protein often mutated in several cancers has been shown to be safe, resulting in durable remissions, in a study of acute myeloid leukemia (AML) with relapsed or refractory ...

New inhibitor drug shows promise in relapsed leukemia

June 21, 2017
A new drug shows promise in its ability to target one of the most common and sinister mutations of acute myeloid leukemia (AML), according to researchers at the Perelman School of Medicine at the University of Pennsylvania ...

Positive results for phase 1 trial of ivosidenib against AML

June 3, 2018
Early phase clinical trial results presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018 of 258 patients with IDH1+ acute myeloid leukemia (AML) treated with the IDH1 inhibitor ivosidenib ...

Longer survival for midostaurin and chemotherapy in AML with FLT3

June 26, 2017
(HealthDay)—For patients with acute myeloid leukemia (AML) and a FLT3 mutation, midostaurin plus chemotherapy is associated with prolonged overall and event-free survival, according to a study published online June 23 in ...

Phase I clinical trial of anti-cancer drug FF-10101 in patients with relapsed or refractory acute myeloid leukemia

November 10, 2015
FUJIFILM Corporation today announced to conduct a clinical trial of its anti-cancer drug FF-10101 in patients with relapsed or refractory acute myeloid leukemia (AML) in the United States next year. FF-10101 is a new drug ...

More than a third of high-risk leukemia patients respond to an experimental new drug

December 9, 2012
A new drug for patients with acute myeloid leukemia (AML) marked by a specific type of genetic mutation has shown surprising promise in a Phase II clinical trial. In more than a third of participants, the leukemia was completely ...

Recommended for you

Scientists sharpen the edges of cancer chemotherapy with CRISPR

July 13, 2018
Tackling unsolved problems is a cornerstone of scientific research, propelled by the power and promise of new technologies. Indeed, one of the shiniest tools in the biomedical toolkit these days is the genome editing system ...

Looking at the urine and blood may be best in diagnosing myeloma

July 13, 2018
When it comes to diagnosing a condition in which the plasma cells that normally make antibodies to protect us instead become cancerous, it may be better to look at the urine as well as the serum of our blood for answers, ...

Massive genome havoc in breast cancer is revealed

July 12, 2018
In cancer cells, genetic errors wreak havoc. Misspelled genes, as well as structural variations—larger-scale rearrangements of DNA that can encompass large chunks of chromosomes—disturb carefully balanced mechanisms that ...

Study shows biomarker panel boosts lung cancer risk assessment for smokers

July 12, 2018
A four-protein biomarker blood test improves lung cancer risk assessment over existing guidelines that rely solely upon smoking history, capturing risk for people who have ever smoked, not only for heavy smokers, an international ...

Discovering the mechanisms that underlie prostate cancer

July 12, 2018
New research has uncovered insights into the mechanisms that underlie prostate cancer, providing potential targets for new cancer therapies.

New method reveals how well cancer drugs hit their targets

July 12, 2018
Scientists have developed a technique that allows them to measure how well cancer drugs reach their targets inside the body. It shows individual cancer cells in a tumour in real time, revealing which cells interact with the ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.